Compass Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $850,000 | $0 | — | — |
| Research and development | $56.0M | $42.3M | $38.1M | $30.0M | $20.3M |
| Operating expenses | $72.8M | $57.5M | $50.4M | $41.7M | $81.9M |
| Operating income | -$72.8M | -$56.6M | -$50.4M | -$41.7M | -$81.9M |
| Interest expense | — | — | — | $0 | $370,000 |
| Pretax income | — | — | -$42.5M | -$39.2M | -$82.2M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$66.5M | -$49.4M | -$42.5M | -$39.2M | -$82.2M |
| Balance Sheet | |||||
| Cash and equivalents | $30.6M | $43.5M | $24.2M | $34.9M | $144.5M |
| Current assets | $209.8M | $132.8M | $153.9M | $194.8M | $147.1M |
| Total assets | $219.6M | $140.4M | $156.9M | $199.6M | $153.8M |
| Current liabilities | $14.0M | $8.9M | $7.8M | $16.2M | $10.6M |
| Total liabilities | $22.8M | $15.2M | $8.3M | $18.0M | $13.7M |
| Stockholders' equity | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$49.1M | -$44.9M | -$40.6M | -$34.1M | -$19.7M |
| Depreciation and amortization | $300,000 | $600,000 | $700,000 | $800,000 | $600,000 |
| Stock-based compensation | $8.4M | $8.6M | $6.1M | $5.3M | $4.0M |
| Capital expenditure | $25,000 | $44,000 | $30,000 | $212,000 | $1.6M |
| Free cash flow | -$49.2M | -$44.9M | -$40.6M | -$34.3M | -$21.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 180.1M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.